Arrowhead Pharmaceuticals prices upsize convertible notes offering to $625M and stock offering at $64.50

Arrowhead Pharmaceuticals (ARWR) announced its public offerings, pricing $625M of 0.00% convertible senior notes due in 2032 and 3.1M shares of common stock at $64.50 per share. Instead of common ...
Nasdaq

Arrowhead price target lowered to $45 from $62 at Piper Sandler

Piper Sandler lowered the firm’s price target on Arrowhead (ARWR) to $45 from $62 and keeps an Overweight rating on the shares. The firm notes Arrowhead entered a strategic partnership with Sarepta ...
Nasdaq

Arrowhead price target raised to $80 from $60 at H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Arrowhead (ARWR) to $80 from $60 and keeps a Buy rating on the shares after the company recently announced a global license ...
Business Insider

Arrowhead price target lowered to $38 from $51 at B. Riley

B. Riley lowered the firm’s price target on Arrowhead (ARWR) to $38 from $51 and keeps a Buy rating on the shares following the fiscal Q1 report. The firm says Ionis Pharmaceuticals’ (IONS) Tryngolza ...
Business Insider

Buy Rating for Arrowhead Pharmaceuticals Amidst Pipeline Progress and Strategic Financial Positioning

Jason Gerberry, an analyst from Bank of America Securities, reiterated the Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report). The associated price target is $51.00. Jason Gerberry has ...
Hosted on MSN

Arrowhead price target raised to $85 from $80 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Arrowhead (ARWR) to $85 from $80 and keeps a Buy rating on the shares. The firm says the company’s “transformative” fiscal Q4 was driven by FDA ...